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Objectives. This study sought to evaluate whether regional
sympathetic myocardial denervation in diabetes is associated with
abnormal myocardial blood flow under rest and adenosine-
stimulated conditions.
Background. Diabetic autonomic neuropathy (DAN) has been
invoked as a cause of unexplained sudden cardiac death, poten-
tially by altering electrical stability or impairing myocardial blood
flow, or both. The effects of denervation on cardiac blood flow in
diabetes are unknown.
Methods. We studied 14 diabetic subjects (7 without DAN, 7
with advanced DAN) and 13 nondiabetic control subjects without
known coronary artery disease. Positron emission tomography
using carbon-11 hydroxyephedrine was used to characterize left
ventricular cardiac sympathetic innervation and nitrogen-13 am-
monia to measure myocardial blood flow at rest and after intra-
venous administration of adenosine (140 mg/kg body weight per
min).
Results. Persistent sympathetic left ventricular proximal wall
innervation was observed, even in advanced neuropathy. Rest
myocardial blood flow was higher in the neuropathic subjects
(109 6 29 ml/100 g per min) than in either the nondiabetic (69 6
8 ml/100 g per min, p < 0.01) or the nonneuropathic diabetic
subjects (79 6 23 ml/100 g per min, p < 0.05). During adenosine
infusion, global left ventricular myocardial blood flow was signif-
icantly less in the neuropathic subjects (204 6 73 ml/100 g per
min) than in the nonneuropathic diabetic group (324 6 135
ml/100 g per min, p < 0.05). Coronary flow reserve was also
decreased in the neuropathic subjects, who achieved only 46%
(p < 0.01) and 44% (p < 0.01) of the values measured in
nondiabetic and nonneuropathic diabetic subjects, respectively.
Assessment of the myocardial innervation/blood flow relation
during adenosine infusion showed that myocardial blood flow in
neuropathic subjects was virtually identical to that in nonneuro-
pathic diabetic subjects in the distal denervated myocardium but
was 43% (p < 0.05) lower than that in the nonneuropathic diabetic
subjects in the proximal innervated segments.
Conclusions. DAN is associated with altered myocardial blood
flow, with regions of persistent sympathetic innervation exhibiting
the greatest deficits of vasodilator reserve. Future studies are
required to evaluate the etiology of these abnormalities and to
evaluate the contribution of the persistent islands of innervation
to sudden cardiac death complicating diabetes.
(J Am Coll Cardiol 1998;31:1575–84)
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Diabetic autonomic neuropathy (DAN) commonly compli-
cates diabetes (1,2) and is associated with increased mortality
rates that range between 16% and 53% over 5 years (3–9).
Classically DAN is associated with an overall decrease in
myocardial sympathetic innervation (7,8). Functional cardiac
abnormalities in diabetic patients without coronary artery
disease (CAD) include defects in ventricular function (10–13)
and rhythm disturbances (14,15) that correlate with the pres-
ence of DAN (12,13). In nondiabetic patients, autonomic
imbalance and in particular regional cardiac sympathetic hy-
peractivity increases the risk of cardiac arrhythmias during
myocardial ischemia (16–18). Selective cardiac sympathetic
denervation or beta-adrenergic blocking agents reduces the
risk of arrhythmias and sudden death in these patients (18).
Thus, cardiac sympathetic hyperactivity in combination with
regional or generalized myocardial perfusion defects may
confer significant added risk of cardiac morbidity or mortality,
or both. Whether cardiac sympathetic hyperactivity itself con-
tributes to impaired myocardial blood flow is controversial,
because both increased (19) or unchanged flow (20) has been
reported after experimental cardiac denervation. In diabetic
patients, the increased cardiac mortality (3–9,21–24) paradox-
ically appears to be further augmented by diminished sympa-
thetic activity in the presence of DAN (3,6–9,21), which may
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facilitate malignant cardiac arrhythmogenesis (3–9). More-
over, diabetic patients demonstrate greatly enhanced cardio-
protection from beta-blockade (21–23), suggesting that adren-
ergic hyperactivity contributes to the exaggerated cardiac risk
in these subjects.
The myocardial blood flow response to sympathetic acti-
vation and consequent norepinephrine release is complex:
coronary alpha–adrenoreceptor-mediated vasoconstriction is
opposed by alpha2- and beta-adrenoreceptors mediating vaso-
dilation and also by localized release of vasodilator metabolites
(25), including adenosine (26). The net effect of sympathetic
activation normally is coronary vasodilation (27–29). However,
several observations suggest that this balance could be de-
ranged and possibly reversed by diabetes. First, subjects with
DAN demonstrate accentuated regional myocardial auto-
nomic imbalance, because left ventricular sympathetic dener-
vation is heterogeneous (12,30). Second, diabetes is associated
with impaired endothelium-dependent vascular relaxation (31–
34) such that the release of vasodilating agents is impaired,
thereby allowing the vasoconstrictive response to adrenergic
agonists to predominate (28,29). We hypothesize that in
diabetes, preserved regional cardiac sympathetic innervation
may result in functional regions of hyperinnervation that would
restrict local blood flow and may on sympathetic activation
precipitate local paradoxical vasoconstriction and ischemia.
These regions of retained innervation may therefore become
the focus of electrical and chemical instability and promote
cardiac arrhythmias and myocardial dysfunction.
Radiolabeled analogues of norepinephrine, which are re-
tained by the sympathetic nerve terminals of the heart (35,36),
permit direct spatial mapping of cardiac sympathetic integrity
(30). The radiotracer C-11 hydroxyephedrine (C-11 HED),
recently developed as a norepinephrine analogue for positron
emission tomography (PET) (30,35,36), undergoes highly spe-
cific uptake and retention in the sympathetic nerve terminals
(35,36). This permits the quantitative regional characterization
of sympathetic neuronal dysfunction and loss (30,35,36).
Therefore, in order to evaluate the effects of diabetes-induced
heterogeneous myocardial sympathetic innervation on myocar-
dial blood flow, we used C-11 HED and PET to directly
characterize left ventricular cardiac sympathetic innervation in
diabetic patients with and without DAN and compared this to
myocardial blood flow measured using N-13 ammonia (37) at
rest and after maximal coronary vasodilation with adenosine
(38).
Methods
Patients. Three groups of patients were studied: insulin-
dependent (type 1) diabetic subjects without DAN, insulin-
dependent diabetic subjects with advanced DAN, and age-
matched nondiabetic control subjects. Clinical details are given
in Table 1. All diabetic subjects were recruited from the
Michigan Diabetes Research and Training Center Clinical
Core. This Core includes a Complications Clinic, in which all
subjects have evidence of diabetic neuropathy, retinopathy or
nephropathy alone or in combination, and a Continuing Care
Clinic in which the patients have no evidence of chronic
diabetic complications. Approximately 30 consecutive presen-
tations to the Complications Clinic were screened in order to
identify the seven eligible subjects with DAN presented herein.
Age- and diabetes duration–matched nonneuropathic diabetic
subjects were recruited from ;20 consecutive presentations to
the Continuing Care Clinic.
The inclusion criteria for all diabetic subjects comprised a
diagnosis of type 1 diabetes; age between 20 and 60 years; the
absence or presence of DAN (as defined below); and the
absence of any risk factors for other causes for neuropathy
(determined by a medical history, family history, history of
medications, occupational history, history of exposure to tox-
ins, physical and neurologic examinations and laboratory stud-
ies). Because the presence of DAN can mask myocardial
ischemia, exercise/stress cardiac studies are standardly per-
formed on these high risk subjects before intensifying their
insulin therapy or initiating an exercise program. Thus all the
subjects with DAN included in this study had undergone
negative cardiac stress testing within the 2-year period preced-
ing this study to confirm the absence of CAD. Exclusion
criteria included preexisting cardiovascular disease, including
CAD, congestive heart failure, known arrhythmias, docu-
Abbreviations and Acronyms
C-11 HED 5 C-11 hydroxyephedrine
CAD 5 coronary artery disease
DAN 5 diabetic autonomic neuropathy
HRV 5 heart rate variability
PET 5 positron emission tomography










Male/female (no.) 9/4 5/2 2/5
Age (yr) 39 6 11 42 6 6 32 6 9
Range 26–54 35–50 20–45
Diabetes duration (yr) — 24 6 12 21 6 10
HbA1c — 8.6 6 0.9 9.8 6 2.7








Total cholesterol 167 6 40 184 6 45 183 6 60
LDL cholesterol 108 6 32 131 6 52 142 6 19
HDL cholesterol 47 6 11 52 6 14 50 6 17
Triglycerides 109 6 74 82 6 58 163 6 67
Data presented are mean value 6 SD, unless otherwise indicated. DAN 5
diabetic autonomic neuropathy; HbAlc 5 hemoglobin Alc; HDL 5 high density
lipoprotein; LDL 5 low density lipoprotein.
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mented ventricular structural abnormalities and valvular dis-
ease, peripheral vascular disease and uncontrolled hyperten-
sion; a history of primary dyslipidemia requiring therapy; a
creatinine clearance ,70 ml/min; or a history of previous
kidney, pancreas or heart transplantation.
The nonneuropathic diabetic subjects (five men, two
women) were selected on the basis of having no evidence of
chronic diabetic complications (thereby reducing the risk of
occult CAD) and having one or no abnormality on standard-
ized cardiac autonomic testing (39–41) and no symptoms of
DAN. Subjects with advanced DAN (two men, five women)
had symptoms attributable to autonomic neuropathy and a
history of hospital admissions with gastroparesis (and abnor-
mal gastric emptying studies). The symptoms that were re-
ported by all subjects with DAN included nausea, early satiety
and periodic episodes of intractable vomiting and persistent
constipation with periodic episodes of diarrhea; five subjects
reported frequent dizziness on standing; and three suffered
from periodic episodes of urinary retention requiring catheter-
ization. All subjects with DAN had two or more abnormalities
of autonomic function on standardized testing (below the 5th
percentile) (39–41) (Table 2). Originally, eight subjects with
DAN were recruited, but one was found to have a discrete
myocardial perfusion deficit after adenosine stimulation and
was excluded from the study. The diabetic subjects were
compared with healthy age-matched nondiabetic subjects (nine
men, four women).
Patients taking medications (including caffeine) known to
interfere with neuronal uptake of norepinephrine analogues
stopped taking their medication for at least 2 weeks before all
studies. Written informed consent was obtained from all
patients and the study protocol was approved by the institu-
tional review board of the University of Michigan.
Autonomic function testing. Cardiovascular autonomic
neuropathy was assessed clinically utilizing a battery of stan-
dardized autonomic function tests (39–41) (Table 2). All
subjects fasted for at least 8 h before testing and were
instructed to delay their morning insulin injection until after
testing. Subjects were excluded if they had experienced a
hypoglycemic episode within 8 h of testing. Blood glucose
values were within the range of 140 to 250 mg/dl during the
assessment period. Heart rate variability (HRV) with deep
breathing was assessed (39–41) by measuring the maximal and
minimal RR intervals and calculating a mean value for the six
cycles. A 5-min postural study was performed in which the
systolic and diastolic blood pressures were recorded three
times at 1-min intervals with the patient supine and the change
in pressures was recorded at 1-min intervals for 5 min after
standing. The lowest standing systolic pressure was used for
calculation of postural change in blood pressure. The Valsalva
maneuver (39) was performed and the ratio of the longest RR
interval after the maneuver to the shortest RR interval during
the maneuver was calculated. This test was repeated twice with
a 5-min period of rest between Valsalva maneuvers and the
mean value calculated. Abnormalities on these standardized
tests were defined as results that were below the 5th percentile
for age (39–41). Skin galvanic responses were recorded from
the hand and foot (42). These skin responses are a measure of
peripheral sympathetic autonomic function because they orig-
inate from synchronized activation of sweat glands by efferent
sympathetic nerve fibers (42). Stimuli consisted of auditory
startle and Valsalva maneuver. Patient responses were re-
corded as present or absent.
PET studies and image construction. Cardiac PET imag-
ing was performed in a whole body PET scanner (model CTI
931 and Siemens/ECAT 931) with 20 mCi C-11 HED and 20
mCi N-13 ammonia over 60 min (30,37). This scanner has eight
circular detector rings that allow for the simultaneous acqui-
sition of 15 contiguous transaxial images (oriented perpendic-
ular to the sagittal and coronal planes of the body) with a slice
thickness of 6.75 mm. After placement of a 22-gauge intrave-
nous cannula in the antecubital vein and positioning the
tomograph with the aid of a scout image, a 15-min transmission
study using a retractable germanium-68 ring source was per-
formed to subsequently correct emission data for tissue atten-
uation. Tracer was injected intravenously and data acquired
dynamically in frame mode to determine tracer activity in both
blood and myocardium (30). After waiting 1 h for the C-11
HED decay after the end of data acquisition, myocardial
perfusion at rest was evaluated using N-13 ammonia. Emission
data were corrected for attenuation and reconstructed using
filtered backprojection utilizing a Hanning filter with a cutoff
frequency of 0.3 cycles/pixel. A SUN workstation (SUN Mi-
crosystems) was used to realign the images perpendicular to
the long axis of the left ventricle, yielding eight short-axis views
(slice thickness 0.8 cm) of myocardial tracer distribution
extending from the apex to the base of the left ventricle.
Homogeneity of C-11 HED retention. The homogeneity of
left ventricular C-11 HED retention was assessed as previously
reported (30,36). Dynamic scan acquisition was initiated simul-
taneously with the injection of C-11 HED and the 60-min
imaging protocol comprised 15 images with varying frame
duration (6 3 30 s, 2 3 60 s, 2 3 150 s, 2 3 300 s, 2 3 600 s,
1 3 1,200 s). Circumferential count-profile analysis was per-
formed on each of the eight short-axis images. Each short-axis
slice was divided into 36 angular regions of interest (“sectors”)







Rest heart rate (beats/min) 71 6 12 92 6 13
HRV (beats/min) 20 6 4 3 6 1
Valsalva ratio 1.9 6 0.3 1.17 6 0.2
Systolic BP fall (mm Hg) 3 6 5 30 6 20
Absent galvanic SP (hand/foot) 0/0 5/5
*Difference between groups for rest heart rate, HRV, Valsalva ratio and
systolic BP fall is p 5 0.006, p 5 0.001, p 5 0.003 and p 5 0.006, respectively,
one-way analysis of variance. Data presented are mean value 6 SD or are
number of patients with absent responses. BP 5 blood pressure; DAN 5
diabetic autonomic neuropathy; HRV 5 heart rate variability; SP 5 skin
potential.
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and the myocardial concentration of C-11 HED in each sector,
as reflected by the mean PET counts in the sector, was
determined. Regional variation of myocardial retention of
C-11 HED was assessed by dividing the mean PET counts in
each of the 288 sectors (8 images 3 36 sectors/image) by the
value found in the sector containing the maximal mean PET
counts. These normalized C-11 HED retention data were then
displayed as polar coordinate maps of relative tracer activity
(C-11/N-13) from the short-axis blood flow and the 30 to
40 min postinjection C-11 HED images. The map was divided
into nine regions as shown schematically in Figure 1. In this
map, the left ventricular myocardium is depicted with the apex
at the center, the distal left ventricular segments (anterior,
septal, inferior and lateral) as the inner ring and the corre-
sponding proximal segments as the outer ring. Apical values
were obtained by averaging together all sectors in the two most
apical short-axis slices. Distal values for the other segments
were obtained by averaging together the appropriate sectors in
the three planes adjacent to the two apical planes. Similarly,
the corresponding proximal values were obtained using the
final three short-axis slices toward the base of the heart.
Evaluation of coronary flow reserve. PET evaluation of
myocardial blood flow detects perfusion abnormalities with
high diagnostic accuracy (43,44). The time course of tracer
distribution in myocardium and blood was defined by dynamic
image acquisition using a previously described method (38,43).
After the transmission scan, 20 mCi N-13 ammonia was
administered into a peripheral arm vein over 30 s. Dynamic
scan acquisition for this study was initiated with varying frame
duration (12 3 10 s, 6 3 30 s, 2 3 300 s). After the baseline
N-13 ammonia study, 50 min was allowed for decay of the N-13
ammonia to ,3% of its initial activity. Intravenous adenosine
was infused into a peripheral vein over 6 min at a dose of
140 mg/kg body weight per min to achieve maximal coronary
vasodilation (38,45). At 3 min, 20 mCi N-13 ammonia was
injected over 30 s and imaged for 3 to 18 min using the same
imaging sequence as the at rest study. Blood pressure and
heart rate were measured at baseline, every minute during
adenosine infusion, and then at 10 and 18 min. Pressure-rate
product was calculated as heart rate times systolic blood
pressure divided by 100.
Twelve myocardial regions per plane were defined in the
eight planes in the last time frame of the dynamic study
sequence. After correction for subject motion, the dynamic
image set was sampled and 96 (8 planes 3 12 regions)
time-activity curves were stored for further analysis. Arterial
input function was determined from circular regions at the two
most basal planes corresponding to the large blood pool at the
center of the largest left ventricle diameter of the resliced
images. A previously validated tracer kinetic model for N-13
ammonia (38) was used to calculate myocardial blood flow in
ml/g per min for the nine regions shown in Figure 1. This three
compartment model represents vascular and extravascular
N-13 ammonia as well as metabolically trapped N-13, which
comprises glutamine (38). In this model, the delivery and
extraction of N-13 ammonia (which is .90% [38]) is used as an
estimate of myocardial blood flow, and the flow values gener-
ated are in close agreement with those obtained by invasive
techniques (38).
Statistical analysis. Statistical analysis was performed us-
ing Super ANOVA (Abacus Concepts Inc.). The equality of
means of the experimental groups was tested by a one-way
analysis of variance, and if significant, the differences were
assessed by the Student-Newman-Keuls multiple range test. If
the variances for the variables were found to differ signifi-
cantly, a logarithmic transformation was performed that cor-
rected the unequal variances. All analyses were then per-
formed on the transformed data. Significance was defined at
the 0.05 level.
Results
Diabetic subjects with DAN had a higher heart rate at rest,
lower HRV and Valsalva ratios, a more pronounced fall in
systolic blood pressure on standing and a high frequency of
absent galvanic skin responses than the nonneuropathic dia-
betic subjects (Table 2).
Homogeneity of C-11 HED retention in the normal left
ventricle. Studies performed in the normal subjects were
processed and averaged together to determine the homogene-
ity of C-11 HED retention in the healthy left ventricle in order
for comparison to be made with the homogeneity of tracer
retention in the diabetic subject groups. Relative C-11 HED
retention in normal subjects ranged from 69 6 7% (mean 6
SD) of the maximal sector activity value in proximal inferior
segments to 82 6 6% in proximal lateral segments. These
regional differences in relative C-11 HED retention did not
achieve statistical significance and were consistent with homo-
geneous uptake of C-11 HED within the normal left ventricle.
Regional C-11 HED retention abnormalities. The hetero-
geneity of regional left ventricular C-11 HED retention in each
diabetic patient was compared with this normal homogeneous
distribution by calculating a z-score, zi 5 (qi 2 mi)/si, where qi
is the relative C-11 HED retention value in the ith sector value
of the diabetic polar map, and mi and si are the mean and
Figure 1. Representation of the left ventricle as a polar map. Individ-
ual profiles were generated for each image, and the map was divided
into nine regions of relative tracer activity. Prox 5 proximal.
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standard deviations of the relative C-11 HED retention in the
ith sector of the control subjects polar map. In the diabetic
subjects, sectors that had a z-score .2.0 (i.e., the relative C-11
HED retention in the patient’s sector was less than the
corresponding sectors mean relative C-11 HED retention in
the normal subjects by .2 SD) were defined as abnormal.
Thus, the calculated z-scores represent a validated (30) mea-
sure of each subject’s myocardial tracer retention heterogene-
ity, with an increase of heterogeneity being consistent with
distal left ventricular denervation (30). The “extent” of the
heterogeneity was expressed as the proportion of sectors in the
polar map that were abnormal (i.e., zi . 2.0).
Left ventricular sympathetic denervation was significantly
more severe in the subjects with DAN than in the diabetic
subjects without DAN. The C-11 HED retention abnormalities
involved 55 6 10% of the left ventricle in subjects with DAN
compared with 3 6 1% of the left ventricle in diabetic subjects
without DAN (p 5 0.001). Although four of seven of the
diabetic subjects without DAN were found to have small
defects in regional C-11 HED retention, none of the deficits
involved .5% of the left ventricle. Among the seven subjects
with DAN, the left ventricular C-11 HED deficits involved
#79% of the ventricle. In all subjects with DAN, C-11 HED
defects were confined to the distal inferior wall of the left
ventricle and progressed proximally with increasing severity of
DAN to involve the distal and proximal anterolateral and
inferior walls. C-11 HED tracer retention was preserved
however in the proximal segments of the anterior and septal
left ventricular walls, even in the subjects with the most
extensive deficits (Fig. 2).
Assessment for occult regional myocardial perfusion de-
fects. The presence of regional discrete perfusion defects
consistent with occult CAD in the study subjects was initially
evaluated by visual and semiquantitative analysis of myocardial
blood flow at rest and during adenosine-induced vasodilation.
Visual inspection of standardized color-coded blood flow
images taken from the distal and proximal short axis and the
vertical and horizontal long axis confirmed homogeneous N-13
ammonia retention (Fig. 2).
Systemic hemodynamic responses to adenosine infusion in
different subject groups. The changes in heart rate, systolic
and diastolic blood pressures and pressure-rate product at rest
and in response to adenosine infusion are shown in Table 3. At
rest the heart rate was higher in the patients with DAN than in
either the nondiabetic subjects or the diabetic subjects without
DAN. Systolic and diastolic blood pressures were also higher in
the subjects with DAN, but this difference did not achieve
statistical significance (p 5 0.08 for systolic blood pressure in
nondiabetic vs. subjects with DAN). No differences were
observed in the hemodynamic response to adenosine infusion
among the subject groups. The rest pressure-rate products
were similar in the nondiabetic subjects and diabetic subjects
without DAN, but significantly increased in those with DAN.
No differences were observed in the pressure-rate product
during adenosine infusion. However, the percent change in
pressure-rate product was lower in the subjects with DAN than
in the diabetic subjects without DAN or nondiabetic control
subjects.
Myocardial blood flow at rest and during adenosine stimula-
tion. Myocardial blood flow at rest differed between groups
(p 5 0.0003) (Fig. 3). It was 58% higher in the subjects with
DAN (109 6 29 ml/100 g per min) than in the nondiabetic
subjects (69 6 3 ml/100 g per min, p , 0.01) and 38% higher
than in the diabetic subjects without DAN (79 6 9 ml/100 g per
min, p , 0.05) (Fig. 3A). Rest regional blood flow was higher
in all myocardial segments in the subjects with DAN than in
Table 3. Change in Heart Rate and Systolic Blood Pressure Before








HR (beats/min) 69 6 12 89 6 17
SBP (mm Hg) 118 6 18 114 6 17
DBP (mm Hg) 76 6 7 70 6 11
PRP 82 6 15 100 6 21 24 6 23
Nonneuropathic diabetic subjects
HR (beats/min) 71 6 11 79 6 11
SBP (mm Hg) 130 6 21 129 6 21
DBP (mm Hg) 76 6 18 73 6 13
PRP 94 6 22 105 6 25 14 6 10
Subjects with DAN
HR (beats/min) 96 6 11† 94 6 14
SBP (mm Hg) 142 6 25 138 6 30
DBP (mm Hg) 88 6 11 78 6 14
PRP 128 6 28† 129 6 26 1 6 10‡
*Results are expressed as the mean value 6 SD. HR, PRP and % change in
PRP differed between groups (p 5 0.0001, p 5 0.0002, p 5 0.02, respectively,
one-way analysis of variance). †p , 0.01 versus nondiabetic and nonneuropathic
diabetic subjects. ‡p , 0.05 versus nondiabetic and nonneuropathic diabetic
subjects. DAN 5 diabetic autonomic neuropathy; DBP 5 diastolic blood
pressure; HR 5 heart rate; PRP 5 pressure-rate product (HR 3 SBP/100);
SBP 5 systolic blood pressure.
Figure 2. PET images of the left ventricle from a 21-year old woman
with DAN who after 13 years of diabetes has symptoms from auto-
nomic neuropathy (gastroparesis and postural hypotension) and ab-
normalities in all her autonomic function tests. Blood flow images
appear normal (top panels), but abnormalities of C-11 HED retention
are extensive, with only the proximal cardiac segments being preserved
(bottom panels). DSA 5 distal short axis; HLA 5 horizontal long axis;
PSA 5 proximal short axis; VLA 5 vertical long axis.
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the other subject groups, with no significant regional differ-
ences in flow emerging within the DAN subject group irrespec-
tive of the extent of the C-11 HED deficits (Fig. 4). Rest blood
flow was similar in nondiabetic subjects and diabetic subjects
without DAN. Adenosine-stimulated myocardial blood flow
differed between groups (p 5 0.04). During adenosine infu-
sion, left ventricular myocardial blood flow was significantly
less in the subjects with DAN (204 6 73 ml/100 g per min) than
in the diabetic group without DAN (324 6 135 ml/100 g per
min, p , 0.05) (Fig. 3B). Although adenosine-stimulated
myocardial blood flow in the subjects with DAN was also 25%
less than in the nondiabetic subjects (273 6 26 ml/100 g per
min) (Fig. 3B), this difference did not achieve statistical
significance (p 5 0.1). Finally, coronary flow reserve was also
found to differ between groups (p 5 0.0001). In the subjects
with DAN, the combination of higher blood flow at rest and a
reduction in adenosine-stimulated flow resulted in a significant
impairment in coronary flow reserve of only 44% (p , 0.01)
and 46% (p , 0.01) versus nonneuropathic diabetic and
nondiabetic control subjects, respectively (Fig. 3C).
Effect of DAN on regional myocardial blood flow during
adenosine simulation. In order to explore the relation between
heterogeneous myocardial sympathetic innervation and myo-
cardial vascular responsiveness during maximal vasodilator
stimulation, rest and adenosine-stimulated regional myocar-
dial blood flow was assessed in the nonneuropathic diabetic
subjects and the subjects with DAN in the distal inferior
myocardial segments where DAN produced near total dener-
vation (97 6 2% C-11 HED retention deficit [Fig. 4]) and in
the proximal anterior myocardial segments, which were rela-
tively unaffected by DAN (5 6 4% C-11 HED retention
deficit). Rest myocardial blood flow in the denervated distal
segments was higher in the subjects with DAN (120 6 33
ml/100 g per min) than in the diabetic subjects without DAN
(80 6 27 ml/100 g per min, p 5 0.04). During adenosine
stimulation this difference disappeared (254 6 110 ml/100 g
per min vs. 304 6 178 ml/100 g per min in diabetic subjects with
and without DAN, respectively, p . 0.5) (Fig. 5, left). Conversely
in the innervated proximal myocardial segments, myocardial
blood flow at rest was not significantly different between the
Figure 3. Comparison of myocardial
blood flow (MBF) to the whole left ven-
tricle under rest conditions (A), during
adenosine stimulation (B) and the coro-
nary flow reserve (CFR) (C) in nondia-
betic control subjects (ND), diabetic sub-
jects without DAN (DAN2) and diabetic
subjects with DAN (DAN1). Data are
shown as mean value 6 SEM. *p , 0.05
versus other groups. **p , 0.05 versus
ND. †p # 0.01 versus other groups.
Figure 4. Polar maps of the extent
of abnormal C-11 HED retention
(shown on the left) and rest myo-
cardial blood flow (shown on the
right) in the nine left ventricular
myocardial segments (see Fig. 1) of
the diabetic subjects with DAN.
Despite a marked heterogeneity of
the extent of the regional C-11
HED deficits (p 5 0.0001, one-way
analysis of variance), myocardial
blood flow at rest was homoge-
neous throughout the left ventricle.
Data are shown as mean value 6
SEM. *p , 0.01 versus proximal
anterior myocardial segments (in
bold).
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subjects with DAN (104 6 25 ml/100 g per min) and those
without DAN (80 6 24 ml/100 g per min, p 5 0.2) (Fig. 5,
right), but adenosine-stimulated myocardial blood flow was
significantly lower in the subjects with DAN (190 6 71 ml/100 g
per min vs. 331 6 137 ml/100 g per min in the nonneuropathic
diabetic subjects, p 5 0.04) (Fig. 5, right). No regional differ-
ences were observed between nondiabetic and nonneuropathic
diabetic subjects under rest or adenosine-stimulated conditions
(data not shown).
Discussion
DAN has been invoked as a cause of unexplained sudden
death in diabetes (3–9) and may enhance cardiac mortality in
diabetic patients with ischemic heart disease (24). To evaluate
whether myocardial sympathetic denervation is associated with
abnormal myocardial blood flow, we compared global and
regional left ventricular sympathetic innervation and blood
flow at rest and after maximal coronary vasodilation with
intravenous adenosine in normal control subjects and diabetic
subjects with and without DAN. The patients with DAN
demonstrated heterogeneous distal cardiac sympathetic dener-
vation with persistent proximal innervation. Globally, in-
creased rest myocardial blood flow, decreased adenosine-
stimulated myocardial flow and reduced coronary flow reserve
accompanied DAN. Reduced global coronary flow reserve in
patients with DAN is consistent with the diminished myocar-
dial perfusion described in diabetic patients with angiographi-
cally normal coronary arteries and normal left ventricular
systolic function (46) (although the neuropathy status was not
reported). During adenosine infusion regional myocardial
blood flow in neuropathic diabetic subjects was virtually iden-
tical to that of the nonneuropathic diabetic subjects in the
distal denervated myocardium but was significantly lower in
the proximal innervated segments. It is thus tempting to
speculate that the persistence of proximal sympathetic inner-
vation is responsible for the regionally blunted vasodilator
response to adenosine.
Elevated global myocardial blood flow at rest was restricted
to patients with DAN and cannot be attributed simply to the
presence of diabetes. This elevated blood flow at rest could
have resulted from the tachycardia at rest (Table 2 [39–41]),
which would increase rest myocardial oxygen consumption and
coronary artery blood flow (47,48). Alternatively, increased
rest global myocardial blood flow in subjects with DAN could
reflect reduced vasoconstricting sympathetic tone or an imbal-
ance of vasoactive agents, or both. The rest tachycardia
commonly reported in DAN (39–41) is conventionally as-
cribed to a more profound reduction of parasympathetic versus
sympathetic tone (39,40). The direct contribution to this
process of the preserved proximal sympathetic innervation
reported here is unknown. Indeed, the presence of an aug-
mented (rather than simply preserved) regional sympathetic
tone stimulating a tachycardia also cannot be conclusively
excluded by these studies. Although rest global blood flow was
greatly increased, rest regional blood flow was similar in the
innervated proximal and denervated distal myocardium of
patients with DAN (Fig. 4). The effects of sympathetic dener-
vation on myocardial blood flow are in general controversial.
Experimental sympathetic myocardial denervation in dogs has
been reported to increase rest myocardial blood flow (19),
decrease collateral vessel resistance (49) and increase collat-
eral blood flow by some (50) but not all (20) investigators.
Sympathectomy has also been reported to stimulate myocar-
dial capillary angiogenesis in the denervated regions (51,52)
and to increase the number of perfused capillaries (53). The
Figure 5. Regional myocardial blood
flow under rest conditions and dur-
ing adenosine stimulation in distal
(left) and proximal (right) myocar-
dial segments. Diabetic subjects
without DAN (DAN2) are shown
in the solid columns and DAN sub-
jects (DAN1) in the hatched col-
umns. Data are shown as mean
value 6 SEM. †p , 0.05 versus
DAN2. *p , 0.05 versus rest flow.
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presence of uniform global rest flow in the regionally dener-
vated myocardium of patients with DAN implies that normal
innervation is not essential to the preservation of vascularity in
the rest state.
In contrast to rest conditions, adenosine-stimulated peak
global left ventricular myocardial blood flow and coronary flow
reserve were significantly reduced in DAN, implicating myo-
cardial denervation as a factor contributing to impaired stim-
ulated blood flow. Paradoxically, regional myocardial vascular
reserve was maximally attenuated in the sympathetically inner-
vated proximal myocardium. Maximal attenuation of vasodila-
tor responsiveness to adenosine in regionally sympathetically
innervated segments most likely reflects one or more of the
following: regionally exaggerated sympathetic tone, regional
vascular hyperresponsiveness or regional histologic microvas-
cular abnormalities. In dogs (28) and normal humans (29),
sympathetic activation or acetylcholine infusion (54) results in
coronary vasodilation. In diabetes or atherosclerosis, however,
endothelial dysfunction may limit the local release of vasodi-
lator agents such as endothelium-derived nitric oxide (31,32)
and eicosanoids (33) or increase the release of endothelin-1
(34), permitting a paradoxical vasoconstrictive response to
norepinephrine (28,29). Because adenosine is an endothelium-
independent vasodilator (37), this study did not directly exam-
ine the effects of DAN on endothelial function. Studies using
endothelium-dependent vasodilator agents are required to
explore these interrelations. Finally, in addition to regional
alterations in myocardial sympathetic innervation in subjects
with DAN, contributions from regional or global myocardial
parasympathetic denervation (6,7,54) (evident from the im-
paired HRV responses [Table 2]) or a denervation-associated
microangiopathy (55,56) cannot be excluded. Therefore
present data cannot definitively explain mechanistically the
paradoxical adenosine-stimulated myocardial blood flow find-
ings in DAN, but other factors in addition to heterogeneous
myocardial sympathetic innervation are probably involved.
Potential clinical implications. The clinical implications of
this pattern of regional cardiac sympathetic dysinnervation and
impaired vascular reactivity in DAN must be viewed in the
light of the following paradox: sympathetic hyperactivity pre-
disposes to sudden death in nondiabetic patients; the hallmark
of advanced DAN that confers increased mortality in diabetic
patients is sympathetic denervation (6–8).
Diabetes is associated with a two- to threefold increase in
the risk of ischemic heart disease and cardiac death, with the
greatest risk observed in non–insulin-dependent (type 2) dia-
betic subjects (57–59). In diabetes, excess cardiac death may be
related to sympathetic hyperactivity or imbalance because
these patients experience proportionately greater cardiopro-
tection from beta-blockade (21–23) with mortality after infarc-
tion being decreased by #63% (22). Regional myocardial
autonomic denervation and altered vascular responsiveness in
DAN may predispose to malignant arrhythmogenesis and
sudden cardiac death. In longitudinal studies, the association
of DAN with increased mortality (3–9) is highest (7,8) in
studies with symptomatic (6) patients with extensive sympa-
thetic and parasympathetic abnormalities on autonomic reflex
testing. Most deaths in these patients result from macro- and
microvascular disease, such as ischemic heart disease and renal
failure, respectively, although cardiorespiratory arrest second-
ary to autonomic denervation has also been implicated (39,40).
Although all the subjects included in the present study had
type 1 diabetes, it seems reasonable to speculate that DAN
may result in a similar pattern of altered regional vascular
responsiveness in type 2 diabetic subjects because these sub-
jects develop an indistinguishable pattern of heterogeneous
left ventricular sympathetic denervation (60–62).
In nondiabetic subjects, high cardiac sympathetic tone may
predispose to ventricular fibrillation by decreasing the arrhyth-
mogenic threshold (57). Malignant ventricular arrhythmias are
associated with cardiac sympathetic hyperactivity, particularly
when accompanied by reduced parasympathetic tone and
myocardial ischemia (16–18). The crude relative risk of sudden
death is doubled (58,59) in these subjects even after correcting
for evidence of cardiac ischemia (62). Our studies have shown
that cardiac denervation in diabetes closely resembles this
pattern of denervation that is thought to predispose to malig-
nant arrhythmias (18,63,64): protective parasympathetic tone
is decreased and sympathetic myocardial innervation is most
preserved in regions incapable of vasodilating during adeno-
sine stimulation. Our studies do however suggest that in the
rest state, the myocardium is well perfused in subjects with
DAN (without CAD) and thus circulatory deficiencies should
not exacerbate arrhythmogenesis under rest conditions. Dur-
ing stress however, relative regional ischemia in sympatheti-
cally innervated regions with diminished parasympathetic pro-
tection may be highly arrhythmogenic.
Conclusions. These studies have demonstrated that DAN
is associated with altered myocardial blood flow, with regions
of persistent sympathetic innervation exhibiting the greatest
deficits of vasodilator reserve. Future studies are required to
evaluate the etiology of these abnormalities and to evaluate the
contribution of the persisting islands of innervation in sudden
cardiac death complicating diabetes.
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